Blake Aftab

Dr. Aftab joined Adicet Bio in April 2021 with nearly 20 years of rich experience in academia, biotech, and pharmaceutical industries developing multiple therapeutic modalities including small molecules, biologics, antibody-drug conjugates, and cell therapies through all stages of drug development. He joins Adicet from Atara Biotherapeutics, Inc., a publicly-traded immunotherapy company, where, as Vice President and Head of Preclinical Science and Translational Medicine, he contributed to the company’s initial transition to cell therapy and led the focus on developing Allo-CAR T cell capabilities. Previously, Dr. Aftab led multiple research programs at the University of California, San Francisco focused on drug discovery and clinical translation in multiple myeloma, including early research supporting targeted approaches for CD38 and other impactful targets of interest for CAR-T therapies. Dr. Aftab received his Ph.D. from The Johns Hopkins University School of Medicine and holds a B.Sc. in Pharmacology and Drug Discovery, from The University of California, Santa Barbara.